DVL2 and breast neoplasm: Using CPTAC breast cancer data cohort from UALCAN analysis platform, we confirmed that the expression of DVL2 in primary breast tumor samples (n = 125) was significantly higher than that in benign breast tissues (n = 18) (p < 0.0001) (Fig. 1A).